Application Of EGFR-TKI In The Treatment Of NSCLC And Its Research Progress In Surgical Assistant And Neoadjuvant Therapy

In recent years, the incidence and mortality of lung cancer are living in the first place in malignant tumor of our country, with non-small cell lung cancer amounts for 80%~85%,the treatment of non-small cell lung cancer should adopt the principle that combine multidisciplinary comprehensive therapy and individualized treatment to maximum prolong the survival time of patients, to enhance the survival rate and delay tumor progression and improve the patient's quality of life. It is only 30-60% for the postoperative NSCLC patients' 5 years survival, preoperative and postoperative chemotherapy can significantly improve the patients' 5 year survival rate, however, many factors allowing chemotherapy into a platform period. As the mechanism of tumor development is gradually clarified,epidermal growth factor receptor(EGFR) enters patients' field of vision, it is a receptor, closely associate with the occurrence and development of tumor, and therefore become the important target of tumor treatment, As the representative of epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI), gefitinib and erlotinib, can selectively block the signal of EGFR, so that achieve the effect of inhibiting tumor growth. EGFR- TKI advantages compared to traditional chemotherapy has been highlighted, and the application in the comprehensive treatment of non-small cell lung cancer have been recognized gradually, and show a certain advantage. At present,there is no definite theory that whether the little toxic and side effect targeted drugs can replace the conventional platinum based dual drug regimen, for using in resectable NSCLC patients' preoperative neoadjuvant therapy or postoperative adjunctive therapy, this article will discuss the above content, and in terms of the latest research progress in targeted drugs used in the adjuvant and neoadjuvant therapy of lung cancer are reviewed. Starting in 2011,two latest research CTONG1103 and CTONG1104, is exploring for whether resectable non-small cell lung cancer can use targeted drugs in both preoperative and postoperative therapy, if there are advantages. We look forward to the results, I believe it will give us a strong basis that the targeted drugs use in resectable NSCLC.